Results 171 to 180 of about 70,337 (231)

Poly ADP Ribose Polymerase Inhibitors Potentiate Proton Therapy End-of-Range Effects by Accelerating Replication Forks and Promoting Transcription Conflict. [PDF]

Int J Radiat Oncol Biol Phys
Han Y, Zhou Q, Dibbs A, Chen B, Weiskittel TM, Remmes NB, Wu Z, Ebner DK, Kloeber JA, Callaghan CM, Bendel AE, Mullikin TC, Laack NN, Xu-Welliver M, Lou Z, Mutter RW.   +15 more
europepmc   +1 more source

Role of poly-ADP-ribose polymerase inhibitors after brain progression in platinum-sensitive ovarian cancer: a case report and review of the literature. [PDF]

Front Oncol
Lendinez-Sanchez G, Diaz-Redondo T, Iglesias-Campos M, Garrido-Almazán L, Alba-Conejo E, Rueda-Dominguez A, Sanchez-Muñoz A.   +6 more
europepmc   +1 more source

Poly (ADP-Ribose) Polymerase inhibitors (PARPi) therapy response in an acral melanoma patient with EMSY gene amplification. [PDF]

JAAD Case Rep
Nassief G, Butt OH, Zhou AY, Ansstas G.
europepmc   +1 more source

Synergistic Cytotoxicity of Histone Deacetylase and Poly-ADP Ribose Polymerase Inhibitors and Decitabine in Breast and Ovarian Cancer Cells: Implications for Novel Therapeutic Combinations. [PDF]

Int J Mol Sci
Valdez BC, Tsimberidou AM, Yuan B, Baysal MA, Chakraborty A, Andersen CR, Andersson BS.   +6 more
europepmc   +1 more source

The promising role of poly(ADP-ribose) polymerase inhibitors in prostate cancer

Asian Journal of Andrology, 2016
Jeanny B Aragon-Ching
doaj   +1 more source

Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells: Implications for novel therapy. [PDF]

Oncotarget
Valdez BC, Tsimberidou AM, Yuan B, Nieto Y, Baysal MA, Chakraborty A, Andersen CR, Andersson BS.   +7 more
europepmc   +1 more source

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testing. [PDF]

ESMO Open
Triner D, Graf RP, Madison RW, Gjoerup O, Tukachinsky H, Ross JS, Quintanilha JCF, Li G, Cheng HH, Pritchard CC, Zurita AJ, Qin Q, Zhang T, Agarwal N, Reichert ZR, Mateo J, Cieslik M, Morgan TM.   +17 more
europepmc   +1 more source

Poly(ADP-ribose) polymerases as modulators of mitochondrial activity [PDF]

, 2019
Bai, Péter, Fodor, Tamás, Liaudet, Lucas, Nagy, Lilla Nikoletta, Pacher, Pál   +4 more
core   +1 more source

Untapped Potential of Poly(ADP-Ribose) Polymerase Inhibitors: Lessons Learned From the Real-World Clinical Homologous Recombination Repair Mutation Testing. [PDF]

World J Oncol
Lebedeva A, Veselovsky E, Kavun A, Belova E, Grigoreva T, Orlov P, Subbotovskaya A, Shipunov M, Mashkov O, Bilalov F, Shatalov P, Kaprin A, Shegai P, Diuzhev Z, Migiaev O, Vytnova N, Mileyko V, Ivanov M.   +17 more
europepmc   +1 more source

Targeted Combination of Poly(ADP-ribose) Polymerase Inhibitors and Immune Checkpoint Inhibitors Lacking Evidence of Benefit: Focus in Ovarian Cancer. [PDF]

Int J Mol Sci
Bailey M, Morand S, Royfman R, Lin L, Singh A, Stanbery L, Walter A, Hamouda D, Nemunaitis J.   +8 more
europepmc   +1 more source